Replies to post #71864 on Biotech Values

[DewDiligence]

Ablynx:

My bigger concern is that the relatively rapid clearance (as compared to full-length mAbs) may limit the therapeutic window substantially. As I've suggested, the acute settings like anticoagulation may be the most advantageous area to test these nanobodies because short exposure and rapid clearance is an advantage.

The fact that Ablynx is pursuing the chronic TTP indication using a subcutaneous formulation (#msg-40720487) suggests that your concern about unduly rapid clearance may be unfounded.